Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

New Company Startup to Launch Genome Information Platform Technology in Japan

By BiotechDaily International staff writers
Posted on 04 Feb 2014
Sony Corp. (Tokyo, Japan) reported that Sony, M3, Inc. (Tokyo, Japan), and Illumina, Inc. (San Diego, CA, USA) have agreed to form a collaboration to launch a genome information platform in Japan.

Sony and M3 will establish a new company with Illumina as a minority investor, by the end of February 2014.

Genome research, which analyzes human genetic data together with medical and other information, has the ability to lead to innovations in identifying the origins of diseases, as well as the development of new pharmaceutical agents and treatment approaches. There is mounting anticipation for new developments in the field of personalized medicine, where drugs or treatments are optimized for the individual patient, and this represents an area where genome research findings are forecast to play an increasingly important role.

The new company’s genome-information platform business will provide a genome analysis service for research institutions and businesses in Japan. It will also aggregate genome data with related information such as medical data to support research in areas where genome data is utilized. The company’s goal will be to contribute to advancements in Japanese customized medicine and healthcare. The extent of its business is expected to extend beyond medical research, to provide a service platform that supports the use of genetic data and medical information for personalized medicine and healthcare services for individual patients.

Tadashi Saito, corporate officer, executive vice president, officer in charge of medical business, Sony Corp., noted, “I’m very excited by the potential of this collaboration to deliver new services and breakthroughs that bring us ever closer to the realization of the personalized medicine and healthcare era. At Sony, we are positioning the medical business as one of our key growth pillars. Together with M3, a Sony Group affiliated company and leader in medical information services, and Illumina, who lead the world in next-generation genome-sequencers, we aim to facilitate genome research that further advances Japanese medical care, and in the future establish a new service platform for the medical industry.”

Itaru Tanimura, representative director of M3, Inc., stated, “The Internet had major impact on our lives. Gene diagnosis and treatment will potentially have the same or even greater influence. The current status of the human genome industry is comparable to the Internet in the early 1990s, when companies such as Google, Amazon, and Facebook had yet to emerge. Going forward, I expect companies and services of this magnitude to also appear in this industry. This three party alliance combines each company’s unique strengths and resources, and together we intend to build a service platform that could not have been realized by others.”

“With the cost of whole genome sequencing falling rapidly, the era of genome-based clinical decisions, personalized medicine, and population health initiatives is on the horizon,” said Jay Flatley, chief executive officer of Illumina. Making use of genomic information for these purposes requires significant data collection and analysis and we are excited to work with Sony and M3 to build a powerful genomic database and lay the groundwork to support population health in Japan.”

P5, Inc. (Tokyo, Japan), which will be the new company’s name, launch is scheduled for end of February 2014, with a capital of JPY 118.75 million.

Related Links:

Sony
M3
Illumina



Channels

Genomics/Proteomics

view channel
Image: Transmission electron micrograph of norovirus particles in feces (Photo courtesy of Wikimedia Commons).

Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.